2Seventy Bio Inc Cash Flow Conversion Efficiency
2Seventy Bio Inc cash flow conversion efficiency. Based on the latest financial reports, 2Seventy Bio Inc (TSVT) has a cash flow conversion efficiency ratio of -0.051x as of March 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-10.97 Million) by net assets ($213.96 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of 2Seventy Bio Inc (2019–2024)
Cash flow conversion efficiency of 2Seventy Bio Inc from 2019 to 2024. This chart illustrates how 2Seventy Bio Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View TSVT share price today for real-time trading data and today's change.
2Seventy Bio Inc Cash Flow Conversion Ratio Explained
2Seventy Bio Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
2Seventy Bio Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of 2Seventy Bio Inc ranked by their cash flow conversion efficiency. Also see market cap of 2Seventy Bio Inc for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Element 29 Resources Inc
V:ECU
|
-0.008x |
|
Envipco Holding N.V.
AS:ENVI
|
0.047x |
|
BioAge Labs, Inc
NASDAQ:BIOA
|
-0.051x |
|
Uchi Technologies Bhd
KLSE:7100
|
0.126x |
|
Chongqing Sifang New Material Co. Ltd.
SHG:605122
|
N/A |
|
Kenmare Resources PLC
IR:KMR
|
0.060x |
|
Grieg Seafood ASA
OL:GSF
|
0.038x |
|
Turvo International Co Ltd
TW:2233
|
0.038x |
Annual Cash Flow Conversion Efficiency for 2Seventy Bio Inc (2019–2024)
The table below shows the annual cash flow conversion efficiency of 2Seventy Bio Inc from 2019 to 2024. Review 2Seventy Bio Inc (TSVT) free cash flow to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $210.81 Million | $-85.00 Million | -0.403x | +38.31% |
| 2023-12-31 | $255.30 Million | $-166.86 Million | -0.654x | +14.43% |
| 2022-12-31 | $310.47 Million | $-237.13 Million | -0.764x | -32.75% |
| 2021-12-31 | $359.82 Million | $-207.03 Million | -0.575x | +36.66% |
| 2020-12-31 | $74.63 Million | $-67.79 Million | -0.908x | +80.91% |
| 2019-12-31 | $43.69 Million | $-207.96 Million | -4.760x | -- |
About 2Seventy Bio Inc
2seventy bio, Inc., a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. The company's products pipeline includes Abecma, a chimeric antigen receptor T-cell product candidates for the treatment of multiple myeloma. It has a collaboration arrangement with Bristol Myers Squibb Company. 2seventy bio, Inc. was inco… Read more